Official ESCRS | European Society of Cataract & Refractive Surgeons
Vienna 2018 Delegate Registration Programme Exhibition Virtual Exhibition Satellites 2018 Survey

 

escrs app advert

Posters

Search Title by author or title

The long-term assessment of visual and refractive outcome of laser in situ keratomileusis for hyperopia using the Amaris 750S® excimer laser 

Poster Details

First Author: M.Sucu TURKEY

Co Author(s):    G. Demir   Y. Yildirim   M. Arici   A. Demirok           

Abstract Details

Purpose:

To evaluate the long-term efficacy and safety of hyperopic laser in situ keratomileusis (LASIK) using the Amaris 750S® (Schwind, eye-tech-solutions, GmbH & Co. KG) excimer laser.

Setting:

Beyoğlu Eye Training and Research Hospital

Methods:

The medical records of one hundred eleven eyes of 62 patients who underwent LASIK for hyperopia using the Amaris 750S® (Schwind, eye-tech-solutions, GmbH & Co. KG) excimer laser were reviewed retrospectively. Patients were divided into three groups based on preoperative spherical equivalent (SE) refraction: low hyperopia (less than +2.50 diopters [D] ), medium hyperopia (+2.75D to +4.00D), and high hyperopia (more than +4.00 D). Uncorrected and best corrected visual acuity (BCVA), long-term stability of refraction, and complications were evaluated.

Results:

In all eyes, the mean preoperative SE was +3.88±1.27 D. At the last visit, the mean SE decreased to +0.96±0.52D. Preoperative uncorrected visual acuity (UCVA) was 0.52±0.34 logMAR and increased to 0.18±0.15 logMAR at 4-years follow-up (p<0.01). There was no statistically significant difference between preoperative and postoperative BCVA. The UCVA was 20/40 or better in 100% of eyes in the low hyperopia group, 93.7% in the medium hyperopia group, and 69,9% in the high hyperopia group. (%89.2 overall) The percentage of eyes within +1.00 D of emmetropia was 88.0%, 50.8%, and 17.4%, respectively (54% overall).

Conclusions:

LASIK is effective and safe for correcting hyperopia. regression is associated with higher degrees of hyperopia and long follow up time.

Financial Disclosure:

None

Back to Poster listing